First-in-child polatuzumab/glofitamab and first-in-human macrophage-modulated CD19 CAR-T therapy (T-ATAX) for refractory Burkitt lymphoma (SITC 2026) - Oct 2, 2026 - Abstract #607; Pres time: Nov 6, 2026; 10:00 AM - 07:00 PM; Location: PCC - Lower Level - North Exhibition Halls 4-5-6; No abstract available
CAR T-Cell Therapy • Clinical • First-in-human • P1 data • Burkitt Lymphoma • Hematological Malignancies • Lymphoma • Oncology
|
|
Daniel Lee; Abraham Sachs; Cynthia Bolsmann; Michael Engel; Emily Moses; Brian Belyea; Kelsey Mueller; Colleen Druzgal; Jeffrey Craig; Daniel Lee
|